ClinicalTrials.gg
Not yet recruitingNCT06401109REFORM-HF IIUpdated May 6, 2024

Naturally Controlled Decongestion Using Renal Independent System in ADHF Patients, a European Registry

An interventional study of AquaPass in Chronic Heart Failure, Fluid Overload and Acute Decompensated Heart Failure, sponsored by AquaPass Medical Ltd.. Not yet recruiting. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-06.

Sponsored by AquaPass Medical Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
21 Years to 80 Years
Sex
All
01

Study summary

The AquaPass is a non-invasive, renal-intended system designed to enhance fluid transfer through the skin, by increasing sweat rate, to treat fluid overload in heart failure patients.

This study will further evaluate the safety, efficacy, and usability of the AquaPass system in the hospital and home settings.

Read the detailed description

The AquaPass system is non-invasive and functions independently of the renal system, targeting the direct removal of fluids directly from the interstitial compartment through the skin, by activating the eccrine sweat glands.

The patient wears a component that is connected to a control unit, which induces warm air to create a controlled environment around the skin, stimulating sweat production. The sweat evaporates instantly, ensuring that the patient remains dry and comfortable.

In this study, the investigators would like to further investigate the efficacy of the system, when used in hospital settings in patients hospitalized for decompensated heart failure and fluid overload, and to continue the treatment in their homes, immediately after the hospitalization, for another 30 days.

02

Conditions studied

  • Chronic Heart Failure
  • Fluid Overload
  • Acute Decompensated Heart Failure
  • Edema

Browse trials for

03

In context

Edema

568 studies on the registry are indexed under Edema; 97 are open to participants now.

This study's planned enrollment of 30 is below the median of 54 across 402 interventional studies indexed under Edema.

Browse Edema studies →

Lead sponsor

AquaPass Medical Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject that was hospitalized with fluid overload and a history of chronic heart failure and CKD stages 1-4
  • Subject has composite congestion score ≥3.
  • Baseline systolic blood pressure at rest of ≥100mmHg.
  • Subject is capable of meeting the following study requirements:
  • For patients with \<30 kg/m2: baseline NT-pro BNP>1,600 pg/ml
  • For patients with BMI >30 kg/m2: baseline NT-pro BNP >800 pg/ml
  • For patients with rate-controlled persistent or permanent AF: NT-pro BNP >2,400 pg/ml.
  • Subject successfully completes 2-4 hours of run-in acclimation session
  • Minimal sweat rate in the last hour of run-in acclimatization of 130gr/hours

Exclusion criteria

Exclusion Criteria:

  • Subject is enrolled to another clinical investigation that might interfere with this study.
  • Baseline systolic blood pressure \<100 mm Hg
  • Subject considered to be in the acute worsening of the heart failure: Requiring ventilation, mechanical support or is clinically unstable requiring pressors, deterioration triggered by arrythmia, infection or other medical condition unrelated to fluid overload.
  • Subject has any known lower body skin problems (open wounds, ulcers)
  • Subject with severe peripheral arterial disease
  • Subject is pregnant or planning to become pregnant within the study period, or lactating mothers.
  • End-stage renal disease (\<15 ml/min/1.73 m2) or requiring dialysis.
  • Inability or unwillingness to comply with the study requirements.
  • History of heart transplant or actively listed for heart transplant or Left Ventricular Assist Device (LVAD).
  • Implanted left ventricular assist device or implant anticipated \<3 months.
  • or other noncardiac condition limiting to \<12 months.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    AquaPass

    Patients hospitalized with chronic heart failure symptoms and fluid overload will be treated in two phases: Phase 1: 'In Hospital' Phase: Patients will be enrolled in the study when admitted to the hospital with fluid overload. Use of the AquaPass system will be performed in the hospital, alongside diuretic therapy. Phase 2: 'At Home' Phase: Upon the investigator's decision at discharge, the patients will be enrolled in this phase of the study, and will receive AquaPass treatment sessions at their home.

    Device: AquaPass

Interventions

  • DeviceAquaPass

    The AquaPass system works by activating the body's natural sweating mechanism to remove excess fluid from the interstitial compartment. This process is achieved by wearing a garment that creates optimal microclimate conditions around the skin. The system is controlled by a portable unit that delivers warm air to the wearable component while ensuring patient safety.

06

What researchers measure

Primary outcomes

  1. Average Sweat Rate Per Hour per patient

    An average sweat rate of 150 ml/hr per patient at hospital and at home

    Time frame: 30 days

  2. Incidence of device- and procedure-related side-effects

    Incidences of system and treatment-related AEs and SAEs including symptomatic changes in vital signs

    Time frame: 30 days

Secondary outcomes

  1. Incidence of worsening renal function

    Incidence of worsening renal function, measured as an increase of Creatinine levels by \>0.5mg/dL

    Time frame: 30 days

  2. Fluid Overload Related Hospitalizations

    Hospitalization or ED visit for decompensated heart failure

    Time frame: 30 days

  3. Changes in congestion score

    to evaluate the effect of the AquaPass treatment on congestion score

    Time frame: 30 days

  4. Changes in Diuretics Dose

    Documentation of changes in diuretics administration to assess safety and potential benefits with system use.

    Time frame: 30 days

  5. Change of quality of life

    Assessment of the quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The minimal score is zero '0' and the highest is '100' when higher scores represent a better outcome for the patient.

    Time frame: 30 days

  6. Changes in NT-ProBNP levels

    Changes in NT-ProBNP levels to demonstrate the system's safety and clinical performance

    Time frame: 30 days

  7. Change in body weight

    To evaluate the effectiveness of the AquaPass System. During the study patients will weighed before and after each treatment. The weight before the first treatment and the weight after the last treatment will be used to assess the treatment performance

    Time frame: 30 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Feb 2026, 12 months later.

Of 168 interventional studies with no phase under Edema, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's planned 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2024
First posted
May 6, 2024
StartEst.
Feb 2025
Primary completionEst.
Feb 2026
CompletionEst.
May 2026
Last update
May 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06401109
Lead sponsor
AquaPass Medical Ltd.
Responsible party
Sponsor
First posted
May 6, 2024
Start date
Feb 2025 (estimated)
Primary completion
Feb 2026 (estimated)
Completion
May 2026 (estimated)
Last update
May 6, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion